Maria Beatriz S Lopes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Beatriz S Lopes has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- David Schiff
University of Virginia, Charlottesville, VA
6 shared publications - Prem Pradeep Batchala
Department of Radiology and Medical Imaging, UVA Health 1215 Lee St, Charlottesville, VA 22908
5 shared publications - Sohil H. Patel
Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, USA
5 shared publications - Camilo E. Fadul
Division of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia, USA
4 shared publications - Edward R. Laws
Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA
4 shared publications - Gabriel Zada
Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
Epigenomic profiling suggests a common origin of both components in mixed gangliocytoma-pituitary neuroendocrine tumors
Mixed gangliocytoma-pituitary neuroendocrine tumors (GC-PitNETs) are rare pituitary tumors composed of neuroendocrine and gangliocytic elements. Recent studies have demonstrated shared features between neuroendocrine and gangliocytic cells. Specifically, co-expression of neuronal-associated cytoskeletal proteins and pituitary cell lineage transcription factors supports the hypothesis of a common origin of the cells in these tumors. In this multi-institutional study, we characterize the epigenomic profiles of a series of GC-PitNETs by DNA methylation analyses. Twenty-two cases, classified according to the 2022 WHO Classification, were studied including 13 somatotroph, 4 corticotroph, 4 mixed somatotroph-lactotroph, and 1 lactotroph GC-PitNETs. DNA methylation profiles of 21 tumors were analyzed using CNS tumor classifiers (Epignostix Heidelberg v12.8 and NCI Bethesda v 3.1), and unsupervised dimensionality reduction methods. The analysis revealed that all 21 evaluated GC-PitNETs exhibited epigenomic profiles aligning strictly with PitNET/adenoma classes matching their WHO histological diagnoses and showing no epigenomic affiliation with neuronal or glioneuronal reference tumors. These findings indicate that the gangliocytic component of GC-PitNETs lacks a distinct epigenomic signature, supporting the hypothesis that these cells may represent transdifferentiated neuroendocrine cells. Consequently, we propose reclassifying GC-PitNETs within tumors of the anterior pituitary neuroendocrine system and be renamed “pituitary neuroendocrine tumor (subtype) with gangliocytic differentiation.”
- 2 November 2026
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
Open AccessEpigenomic profiling suggests a common origin of both components in mixed gangliocytoma-pituitary neuroendocrine tumors
Mixed gangliocytoma-pituitary neuroendocrine tumors (GC-PitNETs) are rare pituitary tumors composed of neuroendocrine and gangliocytic elements. Recent studies have demonstrated shared features between neuroendocrine and gangliocytic cells. Specifically, co-expression of neuronal-associated cytoskeletal proteins and pituitary cell lineage transcription factors supports the hypothesis of a common origin of the cells in these tumors. In this multi-institutional study, we characterize the epigenomic profiles of a series of GC-PitNETs by DNA methylation analyses. Twenty-two cases, classified according to the 2022 WHO Classification, were studied including 13 somatotroph, 4 corticotroph, 4 mixed somatotroph-lactotroph, and 1 lactotroph GC-PitNETs. DNA methylation profiles of 21 tumors were analyzed using CNS tumor classifiers (Epignostix Heidelberg v12.8 and NCI Bethesda v 3.1), and unsupervised dimensionality reduction methods. The analysis revealed that all 21 evaluated GC-PitNETs exhibited epigenomic profiles aligning strictly with PitNET/adenoma classes matching their WHO histological diagnoses and showing no epigenomic affiliation with neuronal or glioneuronal reference tumors. These findings indicate that the gangliocytic component of GC-PitNETs lacks a distinct epigenomic signature, supporting the hypothesis that these cells may represent transdifferentiated neuroendocrine cells. Consequently, we propose reclassifying GC-PitNETs within tumors of the anterior pituitary neuroendocrine system and be renamed “pituitary neuroendocrine tumor (subtype) with gangliocytic differentiation.”
- 8 June 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2180-2181
N-O-D-26-00712—Molecular Classification of Pituitary Neuroendocrine Tumors (PitNETs): Implications for Clinical Management
- 8 June 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2180-2181
N-O-D-26-00712—Molecular Classification of Pituitary Neuroendocrine Tumors (PitNETs): Implications for Clinical Management
- Open Access
- 6 February 2026
- Published by Wiley in Brain Pathology
- Vol. 36 (4) , e70076
Integrated high‐resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34 ‐mutant reveals universal TP53 abnormalities
Diffuse hemispheric glioma, H3 G34‐mutant (DHG‐H3 G34) has been primarily molecularly characterized by methylation profiling and sequencing studies. We describe an integrated histomolecular evaluation including high‐resolution copy number profiling of a series of 60 DHG‐H3 G34 to further our understanding of the spectrum of genetic changes associated with this tumor type. Cases were clinically tested using an 187‐gene mutation and fusion targeted neuro‐oncology next‐generation sequencing panel ( n = 60) and Oncoscan chromosomal microarray ( n = 26) by a single laboratory (2018–2022). A subset of cases had immunohistochemical results for OLIG2 ( n = 42), p53 ( n = 48), and ATRX ( n = 46), and methylation array data ( n = 8). Median age at testing was 21 years (range, 12–50). No significant difference was noted in clinical, histopathological, and mutational profile between pediatric and adult patients. H3‐3A G34 mutations included G34R ( n = 56; 94%), G34V ( n = 3), and a non‐canonical G34E ( n = 1). Concurrent mutations most often involved TP53 ( n = 55; 92%), ATRX ( n = 50; 83%), and PDGFRA ( n = 34; 57%). A reportedly primary tumor was confirmed to be hypermutant and had a PMS2 mutation. A single case also showed an FGFR3::FAM184B fusion. All cases with available chromosomal microarray data had unbalanced genomes, which were often complex (14/26; 54%). The most frequent recurrent copy number abnormalities were losses involving 3q, 4q, 10q, 13q, and 18q, and 17p copy‐neutral loss of heterozygosity (cnLOH) encompassing TP53 . This copy number profile was reminiscent of that seen in Grade 4 IDH‐mutant astrocytomas. Collectively, a TP53 abnormality at copy number (12/26, all cnLOH), sequence (55/60) and protein expression (46/48) level was detected in all 60 cases. In conclusion, integrated high‐resolution copy number and histomolecular analysis expanded the spectrum of genetic changes associated with DHG‐H3 G34, including the presence of universal TP53 abnormalities with frequent cnLOH—a copy number abnormality that has been largely unrecognized—for this new 2021 World Health Organization central nervous system tumor type.
- 6 February 2026
- Published by Wiley in Brain Pathology
- Vol. 36 (4) , e70076
Open AccessIntegrated high‐resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34 ‐mutant reveals universal TP53 abnormalities
Diffuse hemispheric glioma, H3 G34‐mutant (DHG‐H3 G34) has been primarily molecularly characterized by methylation profiling and sequencing studies. We describe an integrated histomolecular evaluation including high‐resolution copy number profiling of a series of 60 DHG‐H3 G34 to further our understanding of the spectrum of genetic changes associated with this tumor type. Cases were clinically tested using an 187‐gene mutation and fusion targeted neuro‐oncology next‐generation sequencing panel ( n = 60) and Oncoscan chromosomal microarray ( n = 26) by a single laboratory (2018–2022). A subset of cases had immunohistochemical results for OLIG2 ( n = 42), p53 ( n = 48), and ATRX ( n = 46), and methylation array data ( n = 8). Median age at testing was 21 years (range, 12–50). No significant difference was noted in clinical, histopathological, and mutational profile between pediatric and adult patients. H3‐3A G34 mutations included G34R ( n = 56; 94%), G34V ( n = 3), and a non‐canonical G34E ( n = 1). Concurrent mutations most often involved TP53 ( n = 55; 92%), ATRX ( n = 50; 83%), and PDGFRA ( n = 34; 57%). A reportedly primary tumor was confirmed to be hypermutant and had a PMS2 mutation. A single case also showed an FGFR3::FAM184B fusion. All cases with available chromosomal microarray data had unbalanced genomes, which were often complex (14/26; 54%). The most frequent recurrent copy number abnormalities were losses involving 3q, 4q, 10q, 13q, and 18q, and 17p copy‐neutral loss of heterozygosity (cnLOH) encompassing TP53 . This copy number profile was reminiscent of that seen in Grade 4 IDH‐mutant astrocytomas. Collectively, a TP53 abnormality at copy number (12/26, all cnLOH), sequence (55/60) and protein expression (46/48) level was detected in all 60 cases. In conclusion, integrated high‐resolution copy number and histomolecular analysis expanded the spectrum of genetic changes associated with DHG‐H3 G34, including the presence of universal TP53 abnormalities with frequent cnLOH—a copy number abnormality that has been largely unrecognized—for this new 2021 World Health Organization central nervous system tumor type.
- Open Access
- 1 December 2024
- Published by Wiley in Brain Pathology
- Vol. 35 (1) , e13323
The 5th Edition of the WHO Classification of Pituitary Tumors: Strengths and limitations
- 1 December 2024
- Published by Wiley in Brain Pathology
- Vol. 35 (1) , e13323
Open AccessThe 5th Edition of the WHO Classification of Pituitary Tumors: Strengths and limitations
- Top Cited PapersOpen Access
- 1 September 2024
- Published by Wiley in Brain Pathology
- Vol. 35 (1) , e13302
The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors
The vast majority of pituitary neuroendocrine tumors (PitNETs) are benign and slow growing with a low relapse rate over many years after surgical resection. However, about 40% are locally invasive and may not be surgically cured, and about one percentage demonstrate an aggressive clinical behavior. Exceptionally, these aggressive tumors may metastasize outside the sellar region to the central nervous system and/or systemically. The 2017 (4th Edition) WHO Classification of Pituitary Tumors abandoned the terminology “atypical adenoma” for tumors previously considered to have potential for a more aggressive behavior since its prognostic value was not established. The 2022 (5th Edition) WHO Classification of the Pituitary Tumors emphasizes the concept that morphological features distinguish indolent tumors from locally aggressive ones, however, the proposed histological subtypes are not consistent with the real life clinical characteristics of patients with aggressive tumors/carcinomas. So far, no single clinical, radiological or histological parameter can determine the risk of growth or malignant progression. Novel promising molecular prognostic markers, such as mutations in ATRX, TP53, SF3B1, and epigenetic DNA modifications, will need to be verified in larger tumor cohorts. In this review, we provide a critical analysis of the WHO guidelines for prognostic stratification and diagnosis of aggressive and metastatic PitNETs. In addition, we discuss the new WHO recommendations for changing ICD‐O and ICD‐11 codes for PitNET tumor behavior from a neoplasm either “benign” or “unspecified, borderline, or uncertain behavior” to “malignant” neoplasm regardless of the clinical presentation, histopathological subtype, and tumor location. We encourage multidisciplinary initiatives for integrated clinical, histological and molecular classification, which would enable early recognition of these challenging tumors and initiation of more appropriate and aggressive treatments, ultimately improving the outcome.
- 1 September 2024
- Published by Wiley in Brain Pathology
- Vol. 35 (1) , e13302
Top Cited PapersOpen AccessThe 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors
The vast majority of pituitary neuroendocrine tumors (PitNETs) are benign and slow growing with a low relapse rate over many years after surgical resection. However, about 40% are locally invasive and may not be surgically cured, and about one percentage demonstrate an aggressive clinical behavior. Exceptionally, these aggressive tumors may metastasize outside the sellar region to the central nervous system and/or systemically. The 2017 (4th Edition) WHO Classification of Pituitary Tumors abandoned the terminology “atypical adenoma” for tumors previously considered to have potential for a more aggressive behavior since its prognostic value was not established. The 2022 (5th Edition) WHO Classification of the Pituitary Tumors emphasizes the concept that morphological features distinguish indolent tumors from locally aggressive ones, however, the proposed histological subtypes are not consistent with the real life clinical characteristics of patients with aggressive tumors/carcinomas. So far, no single clinical, radiological or histological parameter can determine the risk of growth or malignant progression. Novel promising molecular prognostic markers, such as mutations in ATRX, TP53, SF3B1, and epigenetic DNA modifications, will need to be verified in larger tumor cohorts. In this review, we provide a critical analysis of the WHO guidelines for prognostic stratification and diagnosis of aggressive and metastatic PitNETs. In addition, we discuss the new WHO recommendations for changing ICD‐O and ICD‐11 codes for PitNET tumor behavior from a neoplasm either “benign” or “unspecified, borderline, or uncertain behavior” to “malignant” neoplasm regardless of the clinical presentation, histopathological subtype, and tumor location. We encourage multidisciplinary initiatives for integrated clinical, histological and molecular classification, which would enable early recognition of these challenging tumors and initiation of more appropriate and aggressive treatments, ultimately improving the outcome.
- 24 May 2023
- Published by Springer Nature
- p. 1275-1311
Neuroimaging of Brain Tumors in the Era of Radiogenomics
- 24 May 2023
- Published by Springer Nature
- p. 1275-1311
Neuroimaging of Brain Tumors in the Era of Radiogenomics
- Open Access
- 10 May 2023
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-17
SARS-Cov-2 infection and neuropathological findings: a report of 18 cases and review of the literature
Introduction: COVID-19-infected patients harbour neurological symptoms such as stroke and anosmia, leading to the hypothesis that there is direct invasion of the central nervous system (CNS) by SARS-CoV-2. Several studies have reported the neuropathological examination of brain samples from patients who died from COVID-19. However, there is still sparse evidence of virus replication in the human brain, suggesting that neurologic symptoms could be related to mechanisms other than CNS infection by the virus. Our objective was to provide an extensive review of the literature on the neuropathological findings of postmortem brain samples from patients who died from COVID-19 and to report our own experience with 18 postmortem brain samples. Material and methods: We used microscopic examination, immunohistochemistry (using two different antibodies) and PCR-based techniques to describe the neuropathological findings and the presence of SARS-CoV-2 virus in postmortem brain samples. For comparison, similar techniques (IHC and PCR) were applied to the lung tissue samples for each patient from our cohort. The systematic literature review was conducted from the beginning of the pandemic in 2019 until June 1st, 2022. Results: In our cohort, the most common neuropathological findings were perivascular haemosiderin-laden macrophages and hypoxic-ischaemic changes in neurons, which were found in all cases (n = 18). Only one brain tissue sample harboured SARS-CoV-2 viral spike and nucleocapsid protein expression, while all brain cases harboured SARS-CoV-2 RNA positivity by PCR. A colocalization immunohistochemistry study revealed that SARS-CoV-2 antigens could be located in brain perivascular macrophages. The literature review highlighted that the most frequent neuropathological findings were ischaemic and haemorrhagic lesions, including hypoxic/ischaemic alterations. However, few studies have confirmed the presence of SARS-CoV-2 antigens in brain tissue samples. Conclusion: This study highlighted the lack of specific neuropathological alterations in COVID-19-infected patients. There is still no evidence of neurotropism for SARS-CoV-2 in our cohort or in the literature.
- 10 May 2023
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-17
Open AccessSARS-Cov-2 infection and neuropathological findings: a report of 18 cases and review of the literature
Introduction: COVID-19-infected patients harbour neurological symptoms such as stroke and anosmia, leading to the hypothesis that there is direct invasion of the central nervous system (CNS) by SARS-CoV-2. Several studies have reported the neuropathological examination of brain samples from patients who died from COVID-19. However, there is still sparse evidence of virus replication in the human brain, suggesting that neurologic symptoms could be related to mechanisms other than CNS infection by the virus. Our objective was to provide an extensive review of the literature on the neuropathological findings of postmortem brain samples from patients who died from COVID-19 and to report our own experience with 18 postmortem brain samples. Material and methods: We used microscopic examination, immunohistochemistry (using two different antibodies) and PCR-based techniques to describe the neuropathological findings and the presence of SARS-CoV-2 virus in postmortem brain samples. For comparison, similar techniques (IHC and PCR) were applied to the lung tissue samples for each patient from our cohort. The systematic literature review was conducted from the beginning of the pandemic in 2019 until June 1st, 2022. Results: In our cohort, the most common neuropathological findings were perivascular haemosiderin-laden macrophages and hypoxic-ischaemic changes in neurons, which were found in all cases (n = 18). Only one brain tissue sample harboured SARS-CoV-2 viral spike and nucleocapsid protein expression, while all brain cases harboured SARS-CoV-2 RNA positivity by PCR. A colocalization immunohistochemistry study revealed that SARS-CoV-2 antigens could be located in brain perivascular macrophages. The literature review highlighted that the most frequent neuropathological findings were ischaemic and haemorrhagic lesions, including hypoxic/ischaemic alterations. However, few studies have confirmed the presence of SARS-CoV-2 antigens in brain tissue samples. Conclusion: This study highlighted the lack of specific neuropathological alterations in COVID-19-infected patients. There is still no evidence of neurotropism for SARS-CoV-2 in our cohort or in the literature.
- 25 November 2022
- Published by Springer Nature
- p. 711-714
Rathke Cleft Cyst
- 25 November 2022
- Published by Springer Nature
- p. 644-646
Pituicytes
- 25 November 2022
- Published by Springer Nature
- p. 714-716
Rathke Pouch